Structure−Activity Relationships in Platelet-Activating Factor (PAF). 10. From PAF Antagonism to Inhibition of HIV-1 Replication
摘要:
Excessive levels of PAF and cells of macrophage lineage appear to play an important role in neuronal cell injury, inflammatory syndrome, and HIV replication in CNS resulting in AIDS dementia complex (ADC). The beneficial effects of PAF receptor antagonists are evident and give rise to expected therapeutic strategies for neurotrauma. Piperazine derivatives bearing a "cache-oreilles" (ear-muff) electronic distribution are able to inhibit in vitro PAF effects and, thus, could be used in pathologies where this mediator is involved. Therefore, their potential anti-HIV activity was investigated, and we find that (i) these PAF antagonists are effectively active in HIV-infected monocyte-derived macrophages (MDM) but there is no correlation between both anti-HIV and anti-PAF activities; (ii) the presence of a carbamate function (compounds 1a-d) is favorable to the antiviral activity; (iii) the lipophilicity of the substituent on the piperazinic cycle seems to be less important for the anti-PAF activity than for the antiviral one. Our leading compound, PMS 601 (compound la), presents a dual activity with IC50 of 8 and 11 mu M for anti-PAF and anti-HIV activity, respectively, without cytotoxic events at 1000 mu M in MDM. Although its mode of action is not clearly defined, these data suggest that PMS 601, which displays no effect on acellular reverse transcriptase or protease tests, deserves further investigation in the treatment of HIV-1-associated dementia.
An enzymatic approach to bifunctional chelating agents
作者:Paolo Minazzi、Luciano Lattuada、Ivan G. Menegotto、Giovanni B. Giovenzana
DOI:10.1039/c4ob00810c
日期:——
Three novel BFCAs are obtained through an original protocol involving an enzymatic hydrolysis as the key step.
通过一个以酶解作为关键步骤的原创协议,获得了三种新型的双功能纤维素衍生物。
[EN] KRAS G12C INHIBITORS<br/>[FR] INHIBITEURS DE KRAS G12C
申请人:MIRATI THERAPEUTICS INC
公开号:WO2020146613A1
公开(公告)日:2020-07-16
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Inverse Acyl Phosph(on)ates: Substrates or Inhibitors of β-Lactam-Recognizing Enzymes?
作者:Michael J. Morrison、Naixin Li、R.F. Pratt
DOI:10.1006/bioo.2001.1218
日期:2001.10
the synthesis and evaluation as inhibitors of an inverse pair of acylphosph(on)ates that incorporate the amido side chain that represents a major substrate specificity determinant of these enzymes. Thus, N-(phenylacetyl)glycyl phenyl phosphate and benzoyl N-(benzyloxycarbonyl)aminomethyl phosphonate were prepared. The former of these compounds was found to be a substrate of typical class A and C beta-lactamases